98%
921
2 minutes
20
Following accidental radiation exposure due to a radiological or nuclear emergency, a dose assessment should be performed based on biological samples from exposed individuals. Although previous biological dose assessment approaches have focused on nuclear DNA damage in peripheral lymphocytes, this study investigated the radiation-induced impact on the mitochondrial genome, particularly the chronological changes in the mitochondrial DNA copy number (mtDNAcn) following exposure to radiation. We used B-lymphoblastoid cell lines transformed by Epstein-Barr virus established from 12 healthy individuals in their 20s (six males, six females) with or without a history of smoking. Using real-time quantitative PCR, we determined the mtDNAcn from the B cells cultured for 6, 24, and 96 h and after exposure to 0, 1, 2, and 4 Gy X-rays. We found a significant relationship between the exposed dose and mtDNAcn in the 96-hour post-irradiation cells for non-smoking males, suggesting the possible role of mtDNAcn as a biomarker for dose assessment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2220/biomedres.46.9 | DOI Listing |
Microb Drug Resist
September 2025
Drug Discovery Research, Wockhardt Research Centre, Wockhardt Ltd., Chhatrapati Sambhajinagar, India.
Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice.
View Article and Find Full Text PDFAllergy
September 2025
Institute of Allergology, Charité Universitätsmedizin, Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany.
SYN-53, a multi-strain probiotic food supplement, was recently shown to significantly alleviate allergic rhinoconjunctivitis (ARC) and its symptoms. The diversity and dosage of bacterial strains administered via SYN-53 have been proposed as key drivers of its efficacy. The aim of this study was to assess the role of bacterial diversity and dosage by comparing SYN-53 to a low dose variant (SYN-53-LD), a low diversity variant (SYN-4), and a placebo in the management of ARC.
View Article and Find Full Text PDFBrain Behav
September 2025
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Radiology, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Background: The susceptibility values of the basal ganglia reflect the health status of these nuclei. We aimed to explore the associations between various demographic characteristics, lifestyle factors, and biological factors that have the potential to contribute to magnetic susceptibility and investigate the comprehensive impact of these multiple factors on basal ganglia susceptibility values.
Methods: We included 25,980 participants from the UK Biobank.
Med Sci Monit
September 2025
Department of Anesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum University of Warmia and Mazury, Olsztyn, Poland.
Modern anesthesia, intensive care, and emergency medicine rely heavily on neuromuscular blocking agents (NMBAs), first introduced in 1942. These agents not only facilitate endotracheal intubation but also improve surgical conditions by suppressing muscle responses to stimuli. NMBAs function via depolarizing (eg, succinylcholine) or non-depolarizing mechanisms.
View Article and Find Full Text PDFEur J Neurol
September 2025
Pain Treatment and Evaluation Center, CHU Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France.
Background: Neuropathic pain (NP) is frequently resistant to conventional treatments. Botulinum toxin type A (BT-A) is a recommended option for focal peripheral NP, but the dynamics of its effect in real-life conditions remain poorly characterized.
Objective: To assess BT-A efficacy in a real-world study of patients with focal peripheral NP, over a 1-year follow-up period.